Tiziana takes a deep breath and targets Covid-19

The addition last week of Roche’s anti-IL-6 receptor antibody Actemra to Chinese guidelines for treating patients with Covid-19 has prompted Tiziana Life Sciences to speed the development of its similarly-acting TZLS-501 for the same use. The group’s stock is up 173% on London's AIM so far today.